Table of Content

1. Introduction To Bispecific Antibody
  1.1 Overview
  1.2 Clinical Advancement of Bispecific Antibodies
 
2. Bispecific Antibodies Combination Strategies
  2.1 Chemotherapy
  2.2 Targeted Therapy
  2.3 Immunotherapies
  2.4 Radiotherapy
 
3. Commercially Approved Bispecific Antibodies Insight
  3.1 Company, Indication, Location & MOA
  3.2 Bispecific Antibodies Granted FDA & EMA Designations
 
4. Bispecific Antibodies Proprietary Platforms
 
5. Global & Regional Bispecific Antibody Market Outlook
  5.1 Yearly & Quarterly Sales Insight (2020 to 2024)
  5.2 Approved Bispecific Antibodies Reimbursement Policy
  5.3 Global Bispecific Antibody Market Forecast 2030
 
6. Global Bispecific Antibody Market Trends By Region
  6.1 Japan
  6.2 South Korea
  6.3 US
  6.4 Europe
  6.5 China
  6.6 UK
  6.7 Australia
  6.8 Canada
  6.9 Latin America

 
7. Global Bispecific Antibodies Research & Market Trends By Indications
  7.1 Lymphoma
  7.2 Multiple Myeloma
  7.3 Leukemia
  7.4 Lung Cancer
  7.5 Melanoma
  7.6 Gastrointestinal Cancers
  7.7 Other Cancers
  7.8 Blood Disorders
  7.9 Autoimmune & Inflammatory Diseases
  7.10 Microbial Diseases
  7.11 Ocular Diseases
 
8. Blincyto - Clinical, Patent, Pricing & Sales Insight
  8.1 Overview & Patent Insight
  8.2 Pricing & Dosage Analysis
  8.3 Sales Analysis
 
9. Hemlibra - Clinical, Patent, Pricing & Sales Insight
  9.1 Overview
  9.2 Pricing & Dosage Insight
  9.3 Sales Analysis
 
10. Rybrevant - Clinical, Patent & Pricing Insight
  10.1 Overview
  10.2 Pricing & Dosage Insight
 
11. Vabysmo - Clinical, Patent, Pricing & Sales Insight
  11.1 Overview
  11.2 Pricing & Dosage Insight
  11.3 Sales Analysis

 
12. Lunsumio - Clinical, Patent, Pricing & Sales Insight
  12.1 Overview & Patent Insight
  12.2 Pricing & Dosage Insight
  12.3 Sales Analysis
13. Kaitani – Clinical & Sales Insight
 
14. Tecvayli - Clinical, Patent & Pricing Insight
  14.1 Overview & Patent Insight
  14.2 Pricing & Dosage Insight
  14.3 Sales Analysis
 
15. Columvi - Clinical, Patent, Pricing & Sales Insight
  15.1 Overview & Patent Insight
  15.2 Pricing & Dosage Insight
  15.3 Sales Analysis
 
16. Epkinly - Clinical, Patent, Pricing & Sales Insight
  16.1 Overview
  16.2 Pricing & Dosage Insight
  16.3 Sales Analysis
 
17. Talvey - Clinical, Patent & Pricing Insight
  17.1 Overview & Patent Insight
  17.2 Pricing & Dosage Insight
 
18. Elrexfio - Clinical, Patent & Pricing  Insight
  18.1 Overview
  18.2 Pricing & Dosage Insight
  18.3 Sales Analysis
 
19. Imdelltra - Clinical, Patent, Pricing & Sales Insight
  19.1 Overview & Patent Insight
  19.2 Pricing & Dosage Insight
  19.3 Sales Analysis

 
 
20. Ivonescimab -  Clinical Insight
 
21. Ordspono – Clinical & Sales Insight
  21.1 Overview
  21.2 Sales Analysis
 
22. Ziihera - Clinical, Pricing & Sales Insight
  22.1 Overview
  22.2 Pricing & Dosage
  22.3 Sales Insight
 
23. Bizengri - Clinical, Patent, Pricing & Sales Insight
  23.1 Overview
  23.2 Dosing & Pricing
 
24.    Korjuny - Clinical Insight
 
25. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
  25.1 Research
  25.2 Preclinical
  25.3 Phase-I
  25.4 Phase-I/II
  25.5 Phase-II
  25.6 Phase-II/III
  25.7 Phase-III
  25.8 Preregistration
  25.9 Registered
 
26. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

 
27. Competitive Landscape
  27.1 ABL Bio
  27.2 Abzyme Therapeutics
  27.3 Affimed Therapeutics
  27.4 Akeso Biopharma
  27.5 Alligator Bioscience
  27.6 Amgen
  27.7 Antibody Therapeutics
  27.8 APITBIO
  27.9 Aptevo Therapeutics
  27.10 Astellas Pharma
  27.11 AstraZeneca
  27.12 BioAtla
  27.13 Biosion
  27.14 Biotheus
  27.15 BJ Bioscience
  27.16 EpimAb Biotherapeutics
  27.17 FutureGen Biopharmaceutical
  27.18 Genentech
  27.19 Genmab
  27.20 Gensun Biopharma
  27.21 Harbour BioMed
  27.22 IGM Biosciences
  27.23 I-MAB Biopharma
  27.24 ImmuneOnco Biopharma
  27.25 Innovent Biologics
  27.26 Invenra
  27.27 Janssen Research & Development
  27.28 Kenjockety Biotechnology
  27.29 LaNova Medicines Limited
  27.30 Light Chain Bioscience
  27.31 Linton Pharm
  27.32 Lyvgen Biopharma
  27.33 MacroGenics
  27.34 Merus
  27.35 NovaRock Biotherapeutics
  27.36 Pfizer
  27.37 Phanes Therapeutics
  27.38 Prestige BioPharma
  27.39 Regeneron Pharmaceuticals
  27.40 Revitope
  27.41 Roche
  27.42 Virtuoso Therapeutics
  27.43 Xencor
  27.44 Y-Biologics
  27.45 Zhejiang Shimai Pharmaceutical
  27.46 Zymeworks
 

List of Tables

Table 2-1: Bispecific Antibody & Chemotherapy Combinations in Clinical Trials
Table 2-2: Bispecific Antibody & Targeted Therapy Combinations in Clinical Trials
Table 2-3: Bispecific Antibody & Immunotherapy Combinations in Clinical Trials
Table 2-4: Bispecific Antibody & Radiotherapy Combinations in Clinical Trials

Table 3-1: Approved Bispecific Antibodies
Table 3-2: US - Bispecific Antibodies with Regulatory Designations
Table 3-3: EU - Bispecific Antibodies with Regulatory Designations
Table 3-4: China - Bispecific Antibodies with Regulatory Designations

Table 5-1: Epkinly - Billing Unit Application For Doses
Table 5-2: Talvey - Coverage Summary
Table 5-3: Talvey - Coding Summary
Table 5-4: Elrexfio - HCPCS Codes
Table 5-5: Elrexfio - HCPCS Modifiers
Table 5-6: Imdelltra - Payer Coverage & Reimbursement Details
Table 5-7: Ziihera - ICD-10-CM Codes
Table 5-8: Ziihera - ICD-10-PCS Codes

Table 6-1: US – Some FDA Designated Bispecific Antibodies
Table 6-2: US – Bispecific Antibodies With Recent IND Clearances
Table 6-3: EU - Bispecific Antibodies in Late Stage Clinical Trials
Table 6-4: Latin America - Bispecific Antibodies in Clinical Trials

Table 7-1: Lymphoma - Bispecific Antibodies in Clinical Trials
Table 7-2: Multiple Myeloma - Bispecific Antibodies in Clinical Trials
Table 7-3: Leukemia - Bispecific Antibodies in Clinical Trials
Table 7-4: Lung Cancer - Bispecific Antibodies in Clinical Trials
Table 7-5: Melanoma - Bispecific Antibodies in Clinical Trials
Table 7-6: Gastrointestinal Cancers - Bispecific Antibodies in Clinical Trials

Table 8-1: Blincyto – Active Patents
Table 8-2: Blincyto - Recommended Dosage & Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
Table 8-3: Blincyto - Recommended Dosage & Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
Table 8-4: Blincyto - Recommended Dosage & Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL

Table 10-1: Rybrevant – Premedication
Table 10-2: Rybrevant - Dose Reductions For Adverse Reactions
Table 10-3: Rybrevant - Recommended Dosage Modifications For Adverse Reactions

Table 12-1: Lunsumio – Recommended Treatment Cycles
Table 12-2: Lunsumio - Recommended Premedications
Table 12-3: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome

Table 14-1: Tecvayli - Dosing Schedule
Table 14-2: Tecvayli - Recommended Dosage Modifications For Adverse Reactions

Table 15-1: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 15-2: Columvi - Premedications To Be Administered
Table 15-3: Columvi - Recommendations For Management Of Cytokine Release Syndrome
Table 15-4: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)
Table 15-5: Columvi - Recommended Dosage Modifications For Other Adverse Reactions

Table 16-1: Epkinly - Dosage Schedule
Table 16-2: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
Table 16-3: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 16-4: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions

Table 17-1: Talvey - Weekly Dosing Schedule
Table 17-2: Talvey – Biweekly Dosing Schedule
Table 17-3: Talvey - Recommendations for Management of CRS
Table 17-4: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 17-5: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
Table 17-6: Talvey - Recommended Dosage Modifications For Other Adverse Reactions

Table 18-1: Elrexfio - Dosing Schedule
Table 18-2: Elrexfio – Recommendations For Management Of CRS
Table 18-3: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions

Table 22-1: Ziihera - Dosage Modifications For Adverse Reactions
Table 23-1: Bizengri - Premedications Prior To Infusions
Table 23-2: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions